Protective effect of urantide against ischemia-reperfusion injury via protein kinase C and phosphtidylinositol 3′-kinase - Akt pathway

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 5, 2012, Pages 637-645

  Zhang, Jun Yan ^a   Chen, Zhi Wu ^a   Yao, Hua ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Myocardial ischemia reperfusion; PI3K Akt; PKC; Signaling pathway; Urantide

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CARDIAC AGENT; CHELERYTHRINE; CREATINE KINASE; LACTATE DEHYDROGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; TROPONIN I; URANTIDE; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY;

ANIMALS; BENZOPHENANTHRIDINES; CARDIOTONIC AGENTS; CHROMONES; CREATINE KINASE; L-LACTATE DEHYDROGENASE; MALE; MORPHOLINES; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PEPTIDE FRAGMENTS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TROPONIN I; UROTENSINS;

EID: 84860820045     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y2012-048     Document Type: Article

References (42)

1. Ames, R.S., Sarau, H.M., Chambers, J.K., Willette, R.N., Aiyar, N. V., Romanic, A.M., et al. 1999. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature (Lond.), 401(6750): 282-286. doi:10.1038/45809. PMID: 10499587.
2. Andersen, H.R., Nielsen, T.T., Rasmussen, K., Thuesen, L., Kelbaek, H., Thayssen, P., et al.DANAMI-2 Investigators. 2003. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N. Engl. J. Med. 349(8): 733-742. doi:10.1056/NEJMoa025142. PMID:12930925.
3. Anderson, K.E., Coadwell, J., Stephens, L.R., and Hawkins, P.T. 1998. Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B. Curr. Biol. 8(12): 684-691. doi:10.1016/S0960-9822(98)70274-X. PMID:9637919.
4. Balakumar, P., Rohilla, A., and Singh, M. 2008. Preconditioning and postconditioning to limit ischemia-reperfusion-induced myocardial injury: What could be the next footstep? Pharmacol. Res. 57 (6): 403-412. doi:10.1016/j.phrs.2008.05.006. PMID:18586514.
5. Bousette, N., Patel, L., Douglas, S.A., Ohlstein, E.H., and Giaid, A. 2004. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis, 176(1): 117-123. doi:10.1016/j.atherosclerosis.2004.03. 023. PMID:15306183.
6. Budas, G.R., Churchill, E.N., and Mochly-Rosen, D. 2007. Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury. Pharmacol. Res. 55(6): 523-536. doi:10.1016/j.phrs.2007.04.005. PMID:17576073.
7. Camarda, V., Rizzi, A., Calò, G., Gendron, G., Perron, S.I., Kostenis, E., et al. 2002. Effects of humanurotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch. Pharmacol. 365(2): 141-149. doi:10.1007/ s00210-001-0503-0. PMID:11819032.
8. Chen, Z.W., Yang, Q., Huang, Y., Fan, L., Li, X.W., and He, G.W. 2010. Human urotensin II in internal mammary and radial arteries of patients undergoing coronary surgery. Vascul. Pharmacol. 52(1-2): 70-76. doi:10.1016/j.vph.2009.11.003. PMID:19962453.
9. Cheung, B.M., Leung, R., Man, Y.B., and Wong, L.Y. 2004. Plasma concentration of urotensin II is raised in hypertension. J. Hypertens. 22(7): 1341-1344. doi:10.1097/01.hjh.0000125452. 28861.f1. PMID:15201550.
10. + production. J. Mol. Cell. Cardiol. 34(3): 361-367. doi:10.1006/jmcc.2001.1518. PMID:11945027.
11. Dickinson, J., and Fowler, S.J. 2002. Quantification of proteins on Western blots using ECL. In The protein protocols handbook. Edited by John M. Walker. Humana Press, Totowa, N.J. pp. 429-437.
12. Douglas, S.A., and Ohlstein, E.H. 2000. Urotensin receptors. In The IUPHAR compendium of receptor characterization and classification. Edited by D. Girdlestone. IUPHAR Media, London. pp. 365-372.
13. Douglas, S.A., Tayara, L., Ohlstein, E.H., Halawa, N., and Giaid, A. 2002. Congestive heart failure and expression of myocardial urotensin II. Lancet, 359(9322): 1990-1997. doi:10.1016/S01406736(02)08831-1. PMID:12076554.
14. Douglas, S.A., Dhanak, D., and Johns, D.G. 2004. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol. Sci. 25(2): 76-85. doi:10.1016/j. tips.2003.12.005. PMID:15102493.
15. Downward, J. 1998. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10(2): 262-267. doi:10.1016/S0955-0674(98)80149-X. PMID:9561851.
16. Elshourbagy, N.A., Douglas, S.A., Shabon, U., Harrison, S., Duddy, G., Sechler, J.L., et al. 2002. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br. J. Pharmacol. 136(1): 9-22. doi:10.1038/sj.bjp.0704671. PMID:11976263.
17. Hausenloy, D.J., Tsang, A., and Yellon, D.M. 2005. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc. Med. 15(2): 69-75. doi:10.1016/j.tcm.2005.03.001. PMID:15885573.
18. Institute of Laboratory Animal Research. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
19. Kawamura, S., Yoshida, K., Miura, T., Mizukami, Y., and Matsuzaki, M. 1998. Ischemic preconditioning translocates PKC-d and -3 which mediate functional protection in isolated rat heart. Am. J. Physiol. 275(6 Pt 2): H2266-H2271. PMID:9843828.
20. Kim, A.H., Khursigara, G., Sun, X., Franke, T.F., and Chao, M.V. 2001. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol. Cell. Biol. 21(3): 893-901. doi:10.1128/MCB.21.3.893-901.2001. PMID:11154276.
21. Lovell, M.J., Yasin, M., Lee, K.L., Cheung, K.K., Shintani, Y., Collino, M., et al. 2010. Bone marrow mononuclear cells reduce myocardial reperfusion injury by activating the PI3K/Akt survival pathway. Atherosclerosis, 213(1): 67-76. doi:10.1016/j. atherosclerosis.2010.07.045. PMID:20810112.
22. Maguire, J.J., and Davenport, A.P. 2002. Is urotensin-II the new endothelin? Br. J. Pharmacol. 137(5): 579-588. doi:10.1038/sj.bjp. 0704924. PMID:12381671.
23. Maguire, J.J., Kuc, R.E., Wiley, K.E., Kleinz, M.J., and Davenport, A.P. 2004. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides, 25(10): 1767-1774. doi:10.1016/ j.peptides.2004.01.028. PMID:15476944.
24. Matsubara, M., Ranji, M., Leshnower, B.G., Noma, M., Ratcliffe, S. J., Chance, B., et al. 2010. In vivo fluorometric assessment of cyclosporine on mitochondrial function during myocardial ischemia and reperfusion. Ann. Thorac. Surg. 89(5): 1532-1537. doi:10.1016/j.athoracsur.2010.01.065. PMID:20417773.
25. Morimoto, R., Satoh, F., Murakami, O., Totsune, K., Arai, Y., Suzuki, T., et al. 2008. Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues. Peptides, 29(5): 873-880. doi:10.1016/j.peptides. 2007.06.025. PMID:17686550.
26. Murphy, E., and Steenbergen, C. 2008. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol. Rev. 88(2): 581-609. doi:10.1152/physrev.00024.2007. PMID: 18391174.
27. Patacchini, R., Santicioli, P., Giuliani, S., Grieco, P., Novellino, E., Rovero, P., and Maggi, C.A. 2003. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br. J. Pharmacol. 140(7): 1155-1158. doi:10.1038/sj.bjp.0705555. PMID: 14645137.
28. Ping, P., Zhang, J., Qiu, Y., Tang, X.L., Manchikalapudi, S., Cao, X., and Bolli, R. 1997. Ischemic preconditioning induces selective translocation of protein kinase C isoforms 3 and h in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ. Res. 81(3): 404-414. PMID:9285643.
29. Richards, A.M., and Charles, C. 2004. Urotensin II in the cardiovascular system. Peptides, 25(10): 1795-1802. doi:10. 1016/j.peptides.2004.04.017. PMID:15476948.
30. Richards, A.M., Nicholls, M.G., Lainchbury, J.G., Fisher, S., and Yandle, T.G. 2002. Plasma urotensin II in heart failure. Lancet, 360(9332): 545-546 doi:10.1016/S0140-6736(02)09709-X. PMID:12241661.
31. Sharma, A., and Singh, M. 2000. Possible mechanism of cardioprotective effect of ischaemic preconditioning in isolated rat heart. Pharmacol. Res. 41(6): 635-640. doi:10.1006/phrs.1999.0631. PMID:10816332.
32. Strande, J.L., Hsu, A., Su, J., Fu, X., Gross, G.J., and Baker, J.E. 2007. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res. Cardiol. 102(4): 350-358. doi:10.1007/s00395-007-0653-4. PMID: 17468933.
33. Takai, Y., Kishimoto, A., Inoue, M., and Nishizuka, Y. 1977. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum. J. Biol. Chem. 252(21): 7603-7609. PMID:199593.
34. Tong, H., Imahashi, K., Steenbergen, C., and Murphy, E. 2002. Phosphorylation of glycogen synthase kinase-3b during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ. Res. 90(4): 377-379. doi:10.1161/01.RES.0000012567.95445.55. PMID:11884365.
35. Townsend, P.A., Davidson, S.M., Clarke, S.J., Khaliulin, I., Carroll, C.J., Scarabelli, T.M., et al. 2007. Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly, by reducing oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 293(2): H928-H938. doi:10.1152/ajpheart.01135.2006. PMID:17483234.
36. 2+overload injury in rat myocardium. Circ. Res. 84(10): 1156-1165. PMID:10347090.
37. Xu, X., Cao, Z., Cao, B., Li, J., Guo, L., Que, L., et al. 2009. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Surgery, 146(3): 506-514. doi:10.1016/j.surg.2009.03. 022. PMID:19715808.
38. Yao, L., Kuai, J., Liu, X., Yu, D., Yang, Y., Tao, L., et al. 2009. Pretreatment with fentanyl and propofol attenuates myocardial injury in rabbits with acute hemorrhagic shock. J. Surg. Res. 155((1): 25-31. doi:10.1016/j.jss.2008.07.012. PMID:19059609.
39. Yao, H., Zhang, J.Y., and Chen, Z.W. 2010. Protective effect of urantide against myocardial ischemia-reperfusion injury. Chin. Pharmacol. Bull. 26: 661-666.
40. Yao, H., Zhang, J.Y., and Chen, Z.W. 2011. Effect of urantide on myocardial apoptosis in rats induced by ischemia-reperfusion injury. Chin. J. Pharmacol. Toxicol. 25: 127-134. [In Chinese.]
41. Zhang, Y., Chen, Z.W., Girwin, M., and Wong, T.M. 2005. Remifentanil mimics cardioprotective effect of ischemic preconditioning via protein kinase C activation in open chest of rats. Acta Pharmacol. Sin. 26(5): 546-550. doi:10.1111/j.1745-7254.2005. 00100.x. PMID:15842771.
42. Zu, Y.L., Ai, Y., Gilchrist, A., Maulik, N., Watras, J., Sha'afi, R.I., et al. 1997. High expression and activation of MAP kinase-activated protein kinase 2 in cardiac muscle cells. J. Mol. Cell. Cardiol. 29((8): 2159-2168. doi:10.1006/jmcc.1997.0449. PMID:9281447.